Ticker LaunchReverse merger · Completed · IMUX
Immunic AG (German private company)
Reverse merger with Vital Therapies, Inc. (VTL)
Immunic AG (German private company) merged into Vital Therapies, Inc. (VTL), a Nasdaq-listed biotherapeutic company that ended its ELAD liver failure program, in a reverse merger that takes the private company public. The deal was announced on Jan 6, 2019 and closed on Apr 12, 2019. The combined company trades as Immunic, Inc. (IMUX) on Nasdaq.
Immunic is a clinical-stage biopharmaceutical company developing best-in-class oral therapies for chronic inflammatory and autoimmune diseases, led by IMU-838, which is in Phase 2 studies in ulcerative colitis and relapsing-remitting multiple sclerosis.
- Status
- Completed
- Private company
- Immunic AG (German private company)
- Public company
- Vital Therapies, Inc. (VTL)
- Public company business before
- Nasdaq-listed biotherapeutic company that ended its ELAD liver failure program
- Announced
- Jan 6, 2019
- Closed
- Apr 12, 2019
- Combined company
- Immunic, Inc. (IMUX)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Concurrent financing and investors
- Reverse stock split
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- 8-K (merger completion) Apr 15, 2019
- Exhibit 99.1 (completion press release/exhibit)
- All filings on EDGAR CIK 1280776
Other completed reverse mergers
- China VTV Ltd. (Hong Kong target)into China VTV Limited · May 8, 2019
- Adynxx, Inc.into Alliqua BioMedical, Inc. · May 3, 2019
- Charlie's Chalk Dust, LLCinto True Drinks Holdings, Inc. · Apr 26, 2019
- Oncotelic, Inc.into Mateon Therapeutics, Inc. · Apr 22, 2019
- Gadsden Growth Properties, Inc.into FC Global Realty Incorporated · Apr 5, 2019
- PDS Biotechnology Corporationinto Edge Therapeutics, Inc. · Mar 15, 2019